You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Breast cancer

Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations

  • Technology appraisal guidance
  • Reference number: TA952
  • Published:  21 February 2024
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Resource impact
  2. Guidance into practice

Tools and resources

Tools to help you put the guidance into practice.

Resource impact

  • Resource impact statement

  • Resource impact resource (Excel 985 KB)

    Published:
    26 February 2024

Guidance into practice

  • About the Into practice guide

  • Practical steps to improving the quality of care and services using NICE guidance

Back to top